Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs. Intermittent Zanubrutinib in Older Patients With Mantle Cell Lymphoma
NCT05976763Phase 3Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2023
- Primary completion
- Aug 2038
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zanubrutinib in mantle cell lymphoma (MCL) (3 arms), sponsored by Cancer and Leukemia Group B. Primary endpoints: Progression-Free Survival 1 at 10 years and Progression-Free Survival 2 at 10 years. Started Oct 2023; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05976763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05976763.